- Home
- EXAS vs PSO Comparison
EXAS vs PSO Comparison
Compare EXAS & PSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- PSO
- Stock Information
- Founded
- EXAS 1995
- PSO 1844
- Country
- EXAS United States
- PSO United Kingdom
- Employees
- EXAS N/A
- PSO N/A
- Industry
- EXAS Medical Specialities
- PSO Books
- Sector
- EXAS Health Care
- PSO Consumer Discretionary
- Exchange
- EXAS Nasdaq
- PSO Nasdaq
- Market Cap
- EXAS 10.5B
- PSO 10.7B
- IPO Year
- EXAS N/A
- PSO 2000
- Fundamental
- Price
- EXAS $51.74
- PSO $15.77
- Analyst Decision
- EXAS Strong Buy
- PSO
- Analyst Count
- EXAS 16
- PSO 0
- Target Price
- EXAS $72.80
- PSO N/A
- AVG Volume (30 Days)
- EXAS 2.2M
- PSO 468.1K
- Earning Date
- EXAS 02-19-2025
- PSO 01-01-0001
- Dividend Yield
- EXAS N/A
- PSO 1.87%
- EPS Growth
- EXAS N/A
- PSO 23.43
- EPS
- EXAS N/A
- PSO 0.63
- Revenue
- EXAS $2,692,328,000.00
- PSO $4,485,194,688.00
- Revenue This Year
- EXAS $11.81
- PSO N/A
- Revenue Next Year
- EXAS $11.52
- PSO $3.97
- P/E Ratio
- EXAS N/A
- PSO $23.64
- Revenue Growth
- EXAS 11.91
- PSO N/A
- 52 Week Low
- EXAS $40.62
- PSO $11.69
- 52 Week High
- EXAS $79.62
- PSO $16.43
- Technical
- Relative Strength Index (RSI)
- EXAS 35.28
- PSO 50.56
- Support Level
- EXAS $49.79
- PSO $15.51
- Resistance Level
- EXAS $60.88
- PSO $15.94
- Average True Range (ATR)
- EXAS 2.67
- PSO 0.18
- MACD
- EXAS -0.59
- PSO -0.06
- Stochastic Oscillator
- EXAS 17.58
- PSO 52.89
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About PSO Pearson Plc
U.K.-listed Pearson is the world's largest educational provider. The company has been disposing of noncore businesses such as the Financial Times, The Economist, and publishing house Penguin, and is now focused on being an educational resource and testing provider. While Pearson's primary activity centres on higher-level education, the firm also has significant operations in providing clinical assessments, professional certification and testing.